Nkarta to Participate in Upcoming Investor Conference

Rhea-AI Summary

Nkarta, a biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced its participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 10, 2024, at 12:30 p.m. ET, featuring a fireside chat.

Investors and interested parties can access a live webcast of the event through the Investors section of Nkarta's website (www.nkartatx.com). For those unable to attend live, a replay of the webcast will be archived on the website for approximately 90 days. This conference participation provides an opportunity for Nkarta to showcase its progress and engage with the investment community.

News Market Reaction – NKTX

+4.66%

+4.66% Session move

In the trading session that priced this news, NKTX gained 4.66%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

H.C. Wainwright 26^th Annual Global Investment Conference
September 10, 2024
12:30 p.m. ET – fireside chat

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com

FAQ

When is Nkarta (NKTX) participating in the H.C. Wainwright Global Investment Conference?

Nkarta (NKTX) is participating in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 12:30 p.m. ET.

How can investors access Nkarta's (NKTX) presentation at the investor conference?

Investors can access a live webcast of Nkarta's (NKTX) presentation through the Investors section of the company's website, www.nkartatx.com.

For how long will the replay of Nkarta's (NKTX) investor conference presentation be available?

The replay of Nkarta's (NKTX) investor conference presentation will be archived on the company's website for approximately 90 days.

What type of therapies does Nkarta (NKTX) develop?

Nkarta (NKTX) develops engineered natural killer (NK) cell therapies.